RESUMEN
Various types of Hsp90 inhibitors have been and continue to undergo clinical investigation. One development candidate is the purine-based, synthetic Hsp90 inhibitor 1 (MPC-3100), which successfully completed a phase I clinical study. However, further clinical development of 1 was hindered by poor solubility and consequent formulation issues and promoted development of a more water soluble prodrug. Towards this end, numerous pro-moieties were explored in vitro and in vivo. These studies resulted in identification of L-alanine ester mesylate, 2i (MPC-0767), which exhibited improved aqueous solubility, adequate chemical stability, and rapid bioconversion without the need for solubilizing excipients. Based on improved physical characteristics and favorable PK and PD profiles, 2i mesylate was selected for further development. A convergent, scalable, chromatography-free synthesis for 2i mesylate was developed to support further clinical evaluation.
Asunto(s)
Adenina/análogos & derivados , Alanina/análogos & derivados , Antineoplásicos/síntesis química , Benzodioxoles/química , Proteínas HSP90 de Choque Térmico/antagonistas & inhibidores , Profármacos/síntesis química , Adenina/química , Adenina/farmacología , Alanina/síntesis química , Alanina/metabolismo , Alanina/farmacología , Animales , Antineoplásicos/farmacocinética , Antineoplásicos/farmacología , Benzodioxoles/farmacología , Haplorrinos , Humanos , Mesilatos/síntesis química , Mesilatos/farmacocinética , Mesilatos/farmacología , Ratones , Microsomas Hepáticos/metabolismo , Profármacos/farmacocinética , Profármacos/farmacología , Solubilidad , AguaRESUMEN
A new oxazole scaffold showing great promise in HIV-1 inhibition has been discovered by cell-based screening of an in-house library and scaffold modification. Follow-up SAR study focusing on the 5-aryl substituent of the oxazole core has identified 4k (EC50=0.42µM, TI=50) as a potent inhibitor. However, the analogues suffered from poor aqueous solubility. To address this issue, we have developed broadly applicable potential prodrugs of indazoles. Among them, N-acyloxymethyl analogue 11b displayed promising results (i.e., increased aqueous solubility and susceptibility to enzymatic hydrolysis). Further studies are warranted to fully evaluate the analogues as the potential prodrugs with improved physiochemical and PK properties.
Asunto(s)
Fármacos Anti-VIH/farmacología , Descubrimiento de Drogas , VIH-1/efectos de los fármacos , Indazoles/farmacología , Profármacos/farmacología , Fármacos Anti-VIH/síntesis química , Fármacos Anti-VIH/química , Línea Celular Transformada , Relación Dosis-Respuesta a Droga , Humanos , Indazoles/síntesis química , Indazoles/química , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Profármacos/síntesis química , Profármacos/química , Relación Estructura-ActividadRESUMEN
A novel series of (E)-1-((2-(1-methyl-1H-imidazol-5-yl) quinolin-4-yl) methylene) thiosemicarbazides was discovered as potent inhibitors of IKKß. In this Letter we document our efforts at further optimization of this series, culminating in 2 with submicromolar potency in a HWB assay and efficacy in a CIA mouse model.
Asunto(s)
Quinasa I-kappa B/antagonistas & inhibidores , Inhibidores de Proteínas Quinasas/química , Quinolinas/química , Semicarbacidas/química , Tiourea/análogos & derivados , Animales , Perros , Femenino , Hepatocitos/metabolismo , Ensayos Analíticos de Alto Rendimiento , Humanos , Quinasa I-kappa B/metabolismo , Macaca mulatta , Masculino , Ratones , Inhibidores de Proteínas Quinasas/síntesis química , Inhibidores de Proteínas Quinasas/farmacocinética , Quinolinas/síntesis química , Quinolinas/farmacocinética , Ratas , Semicarbacidas/síntesis química , Semicarbacidas/farmacocinética , Relación Estructura-Actividad , Tiourea/síntesis química , Tiourea/química , Tiourea/farmacocinéticaRESUMEN
A novel series of (E)-1-((2-(1-methyl-1H-imidazol-5-yl) quinolin-4-yl) methylene) thiosemicarbazides was discovered as potent inhibitors of IKKß. In this Letter we document our early efforts at optimization of the quinoline core, the imidazole and the semithiocarbazone moiety. Most potency gains came from substitution around the 6- and 7-positions of the quinoline ring. Replacement of the semithiocarbazone with a semicarbazone decreased potency but led to some measurable exposure.
Asunto(s)
Quinasa I-kappa B/antagonistas & inhibidores , Inhibidores de Proteínas Quinasas/química , Semicarbacidas/química , Animales , Perros , Femenino , Ensayos Analíticos de Alto Rendimiento , Quinasa I-kappa B/metabolismo , Masculino , Microsomas/metabolismo , Inhibidores de Proteínas Quinasas/síntesis química , Inhibidores de Proteínas Quinasas/farmacocinética , Quinolinas/química , Ratas , Semicarbacidas/síntesis química , Semicarbacidas/farmacocinética , Relación Estructura-ActividadRESUMEN
Several series of thieno[2-3-b]pyridine analogues were synthesized and screened for inhibitory activity against eukaryotic elongation factor-2 kinase (eEF2-K). Modifications around several regions of the lead molecules were made, with a ring fusion adjacent to the nitrogen on the thienopyridine core being critical for activity. The most active compound 34 shows an IC(50) of 170 nM against eEF2-K in vitro.
Asunto(s)
Quinasa del Factor 2 de Elongación/antagonistas & inhibidores , Quinasa del Factor 2 de Elongación/metabolismo , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Piridinas/química , Piridinas/farmacología , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Humanos , Concentración 50 Inhibidora , Relación Estructura-ActividadRESUMEN
A novel series of 4-arylaminoquinazolines were identified from a cell-based screening assay as potent apoptosis inducers. Through structure-activity relationship studies, MPC-6827 and its close structural analogue, MPI-0441138, were discovered as proapoptotic molecules and mitotic inhibitors with potencies at low nanomolar concentrations in multiple tumor cell lines. Photoaffinity and radiolabeled analogues of MPC-6827 were found to bind a 55-kDa protein, and this binding was competed by MPC-6827, paclitaxel, and colchicine, but not vinblastine. MPC-6827 effectively inhibited the polymerization of tubulin in vitro, competed with colchicine binding, and disrupted the formation of microtubules in a variety of tumor cell lines, which together showed the molecular target as tubulin. Treatment of MCF-7 breast carcinoma or Jurkat leukemia cells with MPC-6827 led to pronounced G2-M cell cycle arrest followed by apoptosis. Apoptosis, as determined by terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling assay, was preceded by loss of mitochondrial membrane potential, cytochrome c translocation from mitochondria to nuclei, activation of caspase-3, and cleavage of poly(ADP-ribose) polymerase. MPC-6827 was equipotent in an in vitro growth inhibition assay in several cancer cell lines regardless of the expression levels of the multidrug resistance ABC transporters MDR-1 (Pgp-1), MRP-1, and BCRP-1. In B16-F1 allografts and in OVCAR-3, MIAPaCa-2, MCF-7, HT-29, MDA-MB-435, and MX-1 xenografts, statistically significant tumor growth inhibition was observed with MPC-6827. These studies show that MPC-6827 is a microtubule-disrupting agent with potent and broad-spectrum in vitro and in vivo cytotoxic activities and, therefore, MPC-6827 is a promising candidate for development as a novel therapeutic for multiple cancer types.
Asunto(s)
Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Resistencia a Múltiples Medicamentos/fisiología , Quinazolinas/farmacología , Tubulina (Proteína)/efectos de los fármacos , Animales , Antineoplásicos/síntesis química , Caspasas/efectos de los fármacos , Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Humanos , Etiquetado Corte-Fin in Situ , Proteínas de Transporte de Membrana/metabolismo , Ratones , Ratones Desnudos , Quinazolinas/síntesis química , Relación Estructura-Actividad , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Efforts towards developing orally bioavailable HIV-1 maturation inhibitors starting from betulinic acid 1 are described. SAR resulted in improved potency, physicochemical properties, and enhanced oral absorption in rats.
Asunto(s)
Fármacos Anti-VIH/síntesis química , Antivirales/síntesis química , Química Farmacéutica/métodos , VIH-1/metabolismo , Terpenos/química , Administración Oral , Amidas/química , Animales , Fármacos Anti-VIH/farmacología , Antivirales/farmacología , Diseño de Fármacos , Humanos , Concentración 50 Inhibidora , Leucocitos Mononucleares/efectos de los fármacos , Modelos Químicos , Triterpenos Pentacíclicos , Ratas , Triterpenos/química , Ácido BetulínicoRESUMEN
Modulation of Hsp90 (heat shock protein 90) function has been recognized as an attractive approach for cancer treatment, since many cancer cells depend on Hsp90 to maintain cellular homeostasis. This has spurred the search for small-molecule Hsp90 inhibitors. Here we describe our lead optimization studies centered on the purine-based Hsp90 inhibitor 28a containing a piperidine moiety at the purine N9 position. In this study, key SAR was established for the piperidine N-substituent and for the congeners of the 1,3-benzodioxole at C8. These efforts led to the identification of orally bioavailable 28g that exhibits good in vitro profiles and a characteristic molecular biomarker signature of Hsp90 inhibition both in vitro and in vivo. Favorable pharmacokinetic properties along with significant antitumor effects in multiple human cancer xenograft models led to the selection of 28g (MPC-3100) as a clinical candidate.
Asunto(s)
Adenina/análogos & derivados , Benzodioxoles/química , Benzodioxoles/farmacología , Proteínas HSP90 de Choque Térmico/antagonistas & inhibidores , Adenina/química , Adenina/farmacocinética , Adenina/farmacología , Animales , Benzodioxoles/farmacocinética , Cromatografía Líquida de Alta Presión , Descubrimiento de Drogas , Concentración 50 Inhibidora , Ratones , Modelos Moleculares , Relación Estructura-ActividadRESUMEN
Mps1 is a dual specificity protein kinase that is essential for the bipolar attachment of chromosomes to the mitotic spindle and for maintaining the spindle assembly checkpoint until all chromosomes are properly attached. Mps1 is expressed at high levels during mitosis and is abundantly expressed in cancer cells. Disruption of Mps1 function induces aneuploidy and cell death. We report the identification of MPI-0479605, a potent and selective ATP competitive inhibitor of Mps1. Cells treated with MPI-0479605 undergo aberrant mitosis, resulting in aneuploidy and formation of micronuclei. In cells with wild-type p53, this promotes the induction of a postmitotic checkpoint characterized by the ATM- and RAD3-related-dependent activation of the p53-p21 pathway. In both wild-type and p53 mutant cells lines, there is a growth arrest and inhibition of DNA synthesis. Subsequently, cells undergo mitotic catastrophe and/or an apoptotic response. In xenograft models, MPI-0479605 inhibits tumor growth, suggesting that drugs targeting Mps1 may have utility as novel cancer therapeutics.
Asunto(s)
Adenina/análogos & derivados , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Morfolinas/farmacología , Morfolinas/uso terapéutico , Neoplasias/tratamiento farmacológico , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Adenina/aislamiento & purificación , Adenina/farmacología , Adenina/uso terapéutico , Animales , Antineoplásicos/aislamiento & purificación , Línea Celular Tumoral , Células HCT116 , Humanos , Ratones , Ratones Desnudos , Mitosis/efectos de los fármacos , Mitosis/fisiología , Modelos Biológicos , Peso Molecular , Morfolinas/aislamiento & purificación , Neoplasias/patología , Inhibidores de Proteínas Quinasas/aislamiento & purificación , Inhibidores de Proteínas Quinasas/farmacología , Inhibidores de Proteínas Quinasas/uso terapéutico , Bibliotecas de Moléculas Pequeñas/química , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Using a live cell, high-throughput caspase-3 activator assay, we have identified a novel series of 4-anilinoquinazolines as inducers of apoptosis. In this report, we discuss the discovery of 2-chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine, compound 2b (EP128265, MPI-0441138) as a highly active inducer of apoptosis (EC50 for caspase activation of 2 nM) and as a potent inhibitor of cell proliferation (GI50 of 2 nM) in T47D cells. Compound 2b inhibited tubulin polymerization, was effective in cells overexpressing ABC transporter Pgp-1, and was efficacious in the MX-1 human breast and PC-3 prostate cancer mouse models. In contrast to the SAR of 4-anilinoquinazolines as EGFR kinase inhibitors, the methyl group on the nitrogen linker was essential for the apoptosis-inducing activity of 4-anilinoquinazolines and substitution in the 6- and 7-positions of the quinazoline core structure decreased potency.